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The human Na+/K+-ATPase (NKA) is a plasma membrane 
ion pump that uses ATP to help maintain the resting 
potential of all human cells. Inhibition of the NKA leads 
to cell swelling and death. The results of this investiga-
tion show that on cancer cells, the NKA either comes in 
close proximity to, associate with or complexes to impor-
tant cancer-related proteins, and thus can be targeted 
with a new type of precision therapy called the extra-
cellular drug conjugate or EDC. The EDCs reported here 
exhibit EC50 values in the low to mid-picomolar range, 
and signal to noise ratios > 1,000:1, both of which are 
dependent on the cell surface expression of the NKA and 
corresponding cancer-related target. We demonstrate 
that a potent small molecule inhibitor of the NKA can 
be covalently attached to antibodies targeting CD20, 
CD38, CD56, CD147, or dysadherin, to create a series of 
selective and powerful EDCs that kill cancer cells extracel-
lularly by a mechanism resembling necrosis. This is there-
fore a framework for the development of a new type of 
precision therapy wherein exquisite selectivity is achieved 
for targeting extracellular disease-related proteins.
Received 8 February 2016; accepted 2 June 2016; advance online  
publication 19 July 2016. doi:10.1038/mt.2016.119
INTRODUCTION
In mammals, the Na+/K+-ATPase is a prominent example of an 
active cell surface ATPase ion pump that is responsible for main-
taining transmembrane concentration gradients of both sodium 
and potassium.1–7 This ion pump consists of three membrane-
spanning subunits (α, β, and γ) each comprising multiple iso-
forms.8,9 Of the three subunits, only the α-subunit actively pumps 
ions in an ATP-dependent manner, resides predominantly inside 
the cell, and is inhibited by cardiac glycoside (CG) binding.10 
Though it is not known why CGs evolved, it is known that they 
bind a deep extracellular pocket within the α-subunit with high 
affinity and specificity.11–14 Extensive clinical studies have led to 
the approval and wide clinical use of certain CGs for the treatment 
of heart failure.15
Beyond ion trafficking, additional biological activities attrib-
uted to CGs have been reviewed elsewhere.16–19 With regard to 
their antiproliferative activities, CGs have intrigued yet puzzled 
scientists since they were first discovered.20–23 Reasons for the 
intrigue include their nanomolar effective concentrations (EC50) 
and their abilities to act on cancers that are metastatic, hypoxic, 
cytoprotective, and drug resistant.24 Yet after years of research and 
multiple clinical trials, no statistically significant clinical benefit in 
the treatment of cancer has been demonstrated.25 A major reason 
for treatment failure is the narrow therapeutic index (TI) of the 
CG class of drugs.
We set out to determine whether the negative effects of CGs 
elicited on normal tissues could be minimized by the precise tar-
geting of CGs to NKA α-subunit specific protein-protein interac-
tions. One protein known to interact with the α-subunit and be 
overexpressed on the cells of many metastatic cancers is dysad-
herin (DYS) a gamma subunit of the NKA (also known as a FXYD 
family protein).26 Hence, we constructed a new type of antibody 
drug conjugate (ADC) that targets extracellular protein-protein 
interactions and termed these, extracellular drug conjugates or 
EDCs. After demonstrating increases in potency and specificity 
with the initial EDC-DYS conjugate, several other EDCs were 
constructed with other antibodies specific to important cancer 
related proteins (CD20, CD38, CD147, CD56). Here, we present a 
thorough discussion and characterization of these EDCs and their 
therapeutic potential.
RESULTS
EDC construction (CG, mAb, and linker) and the 
effect of linker length
Previous data regarding CGs highlighted the importance of a 
six-member α-pyrone ring, a 14β-OH group, and a C-4 double 
bond.27 For conjugation purposes, previous data also suggested 
that amines within the sugar moiety maintain pharmacologi-
cal properties of CGs.28 Applying this knowledge, we produced 
a library of differentially amino-glycosylated CGs and evalu-
ated their activities. One of the most active CGs in the library, 
scillarenin β-L-aminoxyloside was designated CG1 and used to 
construct the extracellular antibody drug conjugates (EDCs) dis-
cussed throughout this study (Figure 1).
The nine monoclonal antibodies (mAbs) discussed in this 
study are specific to targets that are: (i) commonly known to 
associate with the NKA and considered a metastatic cancer 
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the NKA and cancer related (CD56, CD147)29,30; (iii) suggested 
by the results shown in this study to associate with the NKA and 
current cancer antibody drug targets (CD20, CD38)31,32; (iv) or 
suggested by the results in this study not to associate with the 
NKA (i.e., fibroblast-activating protein (FAP)33 and HER2/neu 
(HER2)); or (v) not expressed on any cell surface (i.e., fluorescein 
or peptide (CONTROLS)).
To select an EDC linker, we conjectured that flexibility and 
length would be critical. We therefore used four distinct bifunc-
tional polyethylene glycol linkers (PEGs) of varying lengths (27 
to 144 Å as measured by bond distances) to conjugate anti-dysad-
herin (DYS) and anti-CD147 (CD147) mAbs to CG1. The activi-
ties of these eight EDCs along with the four linker-CG1 molecules 
alone (devoid mAb) were analyzed in vitro for growth inhibi-
tion activity (Figure 2 (DYS) and Supplementary Figures  S1A 
(CD147) and S1B (Linker-CG1s alone) and Supplementary 
Tables S1A and S1B). In general, EDCs with longer linkers exhib-
ited greater activity (Figure 2a) while linker-CG1 molecules with 
no targeting antibody exhibited the opposite effect (Figure 2b). 
Large inflection points of activity were observed for the DYS con-
jugates having linker lengths between 63 and 105 Å and CD147 
conjugates having linker lengths between 27 and 63 Å. When 
linker-CG1s were attached to antibodies that did not recog-
nize any cell surface protein (EDC-CONTROL), their activities 
were poor and resembled linker-CG1s alone or EDCs with short 
linkers (Supplementary Figure S1c and Supplementary Table S2). 
These results clearly indicated that the targeting antibody and the 
long linkers were both critical to obtaining maximal EDC potency 
and specificity and thus, throughout the rest of the study, we con-
structed and tested EDCs using CG1 covalently attached to target-
ing antibodies via linkers spanning at least 105 Å.
The effects of EDC on cell growth
EDCs were constructed with mAbs specific to the nine distinct 
targets, and their effects on a diverse array of cell types were evalu-
ated (Supplementary Table S2). First, the presence (or absence) 
of the antibody target on the surface of live cells was assessed via 
antibody fluorescent staining of unfixed, live cells (Figure 3 and 
Supplementary Table S2). Next, cell sensitivity to the EDCs was 
assessed at concentrations ranging from 1 to 200,000 pmol/l by 
monitoring cell viability (Figure 3 and Supplementary Table S2). 
In instances where the antibody target was expected or experi-
mentally hypothesized to interact with the NKA, the resulting 
data indicated strong EDC activity and specificity, exemplified by 
the picomolar EC50 values observed for EDC-DYS, EDC-CD147, 
and EDC-CD56. In these examples, cancer cells expressing the 
monoclonal antibody targets were particularly sensitive to the 
corresponding EDC (EC50 values between 80 and 440 pmol/l), 
while cancer cells not expressing the targets were relatively 
resistant (EC50 values > 50,000 pmol/l). Furthermore, control 
Figure 1  EDC parts and construction schematic. Basic components of the EDCs described in this study are: CG1 (the drug), the Linker-CG1, mAb 
and the EDC. CG1 was first synthesized and covalently attached to a bifunctional linker via NHS coupling to make Linker-CG1. After antibody hinge 
region disulfides are reduced, Linker-CG1 is added to form the EDC which was then filtered to remove unbound Linker-CG1. All steps and character-








Molecular Therapy vol. 24 no. 10 oct. 2016 1761
Official journal of the American Society of Gene & Cell Therapy
Precision Therapy to the Cells Surface
conjugates (e.g., EDC-CONTROL 1 and 2) constructed with anti-
bodies that do not stain cells exhibited background levels of activ-
ity (EC50 > 100,000 pmol/l). As predicted, all human cell types 
examined were sensitive to the free unconjugated form of CG1 
(EC50 between 700 and 3,100 pmol/l). These results suggest that 
unlike CG1, in order to achieve subnanomolar EDC activity, cell 
surface antibody target expression was indispensable. It should be 
noted that when CG1 was mixed but not covalently attached to a 
targeting monoclonal antibody and compared to CG1 alone, no 
significant change in cell cytotoxicity was ever observed.
Two of the EDCs synthesized (EDC-CD20 and EDC-CD38) 
against targets not previously known to interact with the NKA 
also displayed potent activities (EC50 between 20 and 100 pmol/l). 
There was no activity above background observed for any of the 
cancer cells treated with EDC-FAP or EDC-HER2 (EC50 >100,000 
pmol/l), even though the presence of both targets was confirmed 
via live cell antibody staining and CG1 sensitivity. Similar negative 
results were obtained with EDC using antibodies to CD19, CD22, 
CD29, CD47, CD71, CD92, CD166, CD221, CD243, and CD326 
(data not shown). With the exception of the Rituximab (anti-CD20 
antibody), none of the naked antibodies tested in this study yielded 
detectable direct cytotoxic effects. To determine if the conjugation 
of CG1 to rituximab was simply an additive effect, we compared 
EDC-CD20 to a mixture of CG1 and Rituximab on cells either sen-
sitive to all three of just CG1 and EDC-CD20. The data shows that 
rituximab does not add to the cytotoxic effects of CG1 even on cells 
sensitive to Rituximab alone (Supplementary Figure S1D).
To test whether the active EDCs were toxic to normal human 
cells, peripheral blood mononuclear cells (PBMCs) collected from 
healthy individuals of varying age and sex were treated with EDC-
DYS, EDC-CD147, EDC-CD20, EDC-CD38, or EDC-CONTROL. 
The effects were monitored by assaying apoptosis (Figure 4 and 
Supplementary Table S2). In contrast to the results obtained with 
cancer cells, EDCs were considerably less cytotoxic to PBMCs 
(EC50 ≥ 100,000 pmol/l). Knowing that endothelial and epithelial 
cells express both dysadherin and CD147 on their surface, EDC-
DYS, EDC-CD147, and EDC-CONTROL were added to cultured 
primary kidney endothelial cells and primary arterial epithelial 
cells. Again the active EDCs were considerably less toxic to the 
normal cells (EC50 > 200,000 pmol/l) than they were to cultured 
tumor cells (EC50 between 60 and 440 pmol/l). Taken together, 
these results indicate that EDCs are specific for the cells express-
ing the corresponding mAb target and may be capable of sensing 
distinct NKA interactions that occur upon tumor transformation.
Mechanism of EDC-mediated cell death and lack of 
internalization
Cell morphology studies were conducted to identify and compare 
the type of cell death induced by EDCs. In the presence of the mem-
brane impermeable dye Sytox Green, A549 cells were treated with 
Figure 2 Effect of linker length on EDC activity. (a) Dose response curves of A549 cells treated with EDCs constructed with the anti-dysadherin 
(DYS) antibody linked to CG1 via four different polyethylene glycol (PEG) linkers with 2 (green diamond), 12 (gold triangle), 24 (blue square), or 36 
(red circle) repeating units spanning different lengths (27, 56, 105, 144 angstroms respectively as measured by bond distances). The figure to the 
right of the graph represent the 4 EDCs in order of activity from higher activity to lower activity (left to right). (b) Dose response curves of A549 cells 
treated with CG1 (black open circle) and 4 the different Linker-CG1s (polyethylene glycol (PEG) polymers with 2 (open green diamond), 12 (open 
gold triangle), 24 (open blue square), or 36 (open red circle) repeating units spanning different lengths (27, 56, 105, 144 angstroms respectively as 
measured by bond distances). The figure to the right of the graph represent the four Linker-CG1s in order of activity from higher activity to lower 
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EDC-DYS, EDC-CD147, siRNA against α-1 (ATP1A1) or two other 
CGs (oleandrin and digitoxin) and imaged with phase-contrast 
microscopy (Figure 5a and Supplementary Figure S2). The results 
show that under any of these conditions, cells began to swell within 
12–24 hours (3–4 days for siAlpha-1) then partially detached from 
the substrate with outer membrane rupture occurring in 2–5 days 
as indicated by staining with the membrane impermeable Syto-
Green dye. This swelling phenotype, termed oncosis, followed by 
membrane rupture is characteristic of necrotic cell death but distinct 
from apoptotic or autophagic death in which cells shrink and bleb or 
display cytoplasmic vacuolization, respectively.34 Consistently, west-
ern blot analysis for apoptosis (Caspase-3 and PARP cleavage) and 
autophagy (LC3B shift or p62 reduction) markers and immunofluo-
rescence analysis of Annexin V binding, all remained unchanged 
(data not shown). Similar swelling and membrane rupture was 
observed when PANC-1, Ramos, SUDHL4 and SUDHL8 cells were 
treated with EDCs or free CGs (data not shown). These results indi-
cate that like free CGs, EDCs induce necrotic cell death.
Figure 3 Antibody target expression is required for EDC activity. (a) Immunofluorescence staining images of live A549, PANC-1, LOX, and H69 
cells stained with antibodies specific to; dysadherin (DYS), CD147, and CD56. (b) Dose response curves for cell lines in a treated with EDC-DYS, 
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To determine whether EDCs internalize or not, we conducted 
a set of experiments using EDC-DYA and EDC-CD38. First, we 
observed the trafficking of EDC-DYS and free antibody DYS after 
addition to H460 cells, an adherent cell line found to be sensi-
tive to EDC-DYS (EC50 = 260 picomolar). Following published 
procedures, after 3 and 20 hours of incubation, cells were fixed, 
permeablized and stained with goat anti-mouse IgG Dylight 
488.35 Fluorescent images showed free antibody and EDC-DYS 
displaying a pattern of mostly surface staining (bright staining 
seen along boarders and junctions of the cells (Supplementary 
Figure S5A). We therefore concluded that the antibody sur-
face receptor-dysadherin complexes were poorly internalized 
upon antibody or EDC-DYS binding. We next observed the 
trafficking of EDC-CD38 after addition to BF01 cells, a non-
adherent cell line known to internalize unconjugated CD38 anti-
bodies.36 Following a different published protocol, EDC-CD38 
was observed only on the cell surface, even after 20 hours of incu-
bation (Supplementary Figure S5B).
EDC target specificity
We next set out to identify which subunits of the NKA were tar-
geted by the EDCs using siRNA experiments. A549 and PANC1 
cells were treated with siRNAs specific to dysadherin, CD147, and 
each of the four alpha and beta subunits of human NKA Cells 
were then treated with EDC-DYS, EDC-CD147, or unconjugated 
CG1 (Figure 5b and Supplementary Figures S3A and S3B). siR-
NAs against α-1 subunit, but not α-2/3/4 resulted in >10-fold 
change in the activities of all three treatments. Knockdown of any 
single β-subunit failed to affect the activities of the treatments 
while simultaneous knockdown of β-1 and β-3 resulted in a 3-fold 
change in their activities. Knockdown of dysadherin and CD147 
expression resulted in resistance to the corresponding EDC yet 
yielded no effect on CG1 activity. Knockdown of each expressed 
isoforms, α-1, β-1, and β-3 and dysadherin was determined by 
western blot analysis (Supplementary Figure S4). Similar results 
were obtained with Panc1 cells (data not shown). These results 
suggest that like CG1, EDCs elicit their effects though the α-1 and 
β-1/3 subunits yet unlike CG1, they were also dependent on the 
expression of the antibody target.
In vivo EDC efficacy
Using human cell lines displaying in vitro EDC sensitivity, animal 
xenograft models were developed and used to evaluate the in vivo 
anticancer activity of three EDCs (Figure 6 and Supplementary 
Figure S6). Three separate xenograft experiments were con-
ducted to examine EDC-DYS:1 direct comparison with CG1,2 
dose escalation, and3 EDC-DYS specificity. Experiments were also 
devised to directly compare the effects of EDC-CD38 to those of 
CHOP (a standard chemotherapy cocktail). Finally, a study was 
conducted to directly compare EDC-CD20 and Rituximab dose 
responsiveness.
Based on our prior dosing results, a single comparator study 
using mice bearing human A549 NSCLC tumors was conducted 
to demonstrate what required dosing would be necessary to 
obtain similar efficacy for CG1, EDC-DYS and paclitaxel. The 
results show that the response to EDC-DYS (5 mg/kg adminis-
tered intravenously (i.v.) every 3 days four times (q3dx4)) was 
comparable to CG1 (20 mg/kg administered i.v. every 2 days five 
times (q2dx5)) and paclitaxel (15 mg/kg iv. every day five times 
(qdx5)) (Supplementary Figure S6A). Only the groups receiving 
CG1 or paclitaxel exhibited mean weight loss >10%. Importantly, 
each EDC in this report has a drug antibody ratio (DAR) of 4, 
thus 5 mg of an EDC equates to 0.07 mg of CG1. Therefore, in 
this study, five administrations of 20 mg of unconjugated CG1 or 
100mgs/kg total should be compared to four administrations of 
0.07 mg of EDC targeted CG1 or 0.28 mg/kg total. The findings 
therefore show that in order to achieve a similar response under 
optimal CG1 dosing, it required 350-fold fewer CG1 equivalents 
when CG1 was targeted via the EDC approach.
Dose escalation studies were based on the intraperitoneal 
injection (i.p.) of 1, 5, and 15 mg/kg of EDC-DYS following two 
distinct schedules into mice bearing human pancreatic cancer 
tumors (Panc1). Results were compared to a standard dosing regi-
men of gemcitabine (Supplementary Figure S6B). The results 
clearly show dose dependency, with 15 mg/kg on either a q3dx7 
or qwkx3 dosing schedule yielding the strongest response (82 and 
Figure 4 Effects of EDC on cell viability. (a) EDC-CD20. (b) EDC-CD38. 
Concentration sensitivity of cancer and normal cells to EDC were com-
pared by determining the percent living cells after exposure using 
two different experimental protocols. Cancer cells were treated with 
EDC-CD20 for 72 hours and viability determined by CellTiter-Glo analy-
sis. peripheral blood mononuclear cells were treated with EDC-CD20 for 
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60% tumor growth inhibition, respectively). Both of these EDC-
DYS dosing regimens outperformed gemcitabine (120 mg/kg 
q3dx4) showing 42% inhibition of tumor growth.
EDC-DYS specificity was directly compared to the unconju-
gated antibody (DYS-mAb) and EDC-CONTROL in mice bear-
ing human B-cell tumors (Ramos) averaging 400 mm3 in size. 
Each preparation was administered at 10 mg/kg i.p. on a q5dx3 
schedule (Supplementary Figure S6C). DYS-mAb and EDC-DYS 
dosing resulted in tumor growth inhibition of 40 and 87%, respec-
tively. EDC-CONTROL had no effect on tumor growth. These 
findings suggest that EDC-DYS efficacy is dependent on the pres-
ence of both the CG1 and the targeting mAb.
The in vivo efficacy of EDC-CD38 was tested and directly com-
pared to CHOP, a standard chemotherapy cocktail. EDC-CD38 
(10 mg/kg at q5dx4 i.p.) and CHOP (CHO qdx1 i.p. and P qdx5 
orally) were administered to mice bearing human Ramos tumors 
(Supplementary Figure S6D). The administration of EDC-CD38 
yielded tumor growth inhibition of 93% as compared to 54% pro-
vided by CHOP, indicating that EDC-CD38 was active in vivo and 
the CD38-NKA interaction was preserved.
Figure 5 Mechanism of action. (a) Phase-contrast imaging of A549 cells, in the presence of the membrane impermeable nucleic acid dye Sytox-
Green, treated with PBS, CG1, EDC-DYS, EDC-CD147, siRNA against ATP1A1, or nontargeting control siRNA (siNT). (b) Cell death dose response 
curves and EC50 values of A549 cells transfected with the indicated siRNAs and treated with CG1, EDC-DYS, or EDC-CD147. α and β refer to the 
subunits of the NKA. NA indicates no activity.
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Finally, the antitumor effects of EDC-CD20 were compared 
to Rituximab, the standard of care for human B-cell lymphoma. 
Mice bearing SUDHL4 tumors were administered single 5 mg/kg 
doses of either EDC-CD20 or Rituximab (Figure 6a). EDC-CD20 
resulted in a tumor growth inhibition of 99%, superior to the 
effects of Rituximab at 79%. Furthermore, only EDC-CD20 
provided a complete eradication of the tumor burden (2/6 mice 
showing no palpable tumors on day 45). Finally, EDC-CD20 
dose response was evaluated by dosing the models with 0.5, 1.5, 
or 5 mg/kg (Figure 6b). Like the results of the EDC-DYS, a dose 
response was observed for EDC-CD20.
DISCUSSION
Antibody-directed drug targeting was first proposed in 1970,37 
and the idea of attaching potent drugs to antibodies such that 
they are directed to diseased cells remains largely unchanged.38 
Reported here are the results of an effort to further develop the 
ADC paradigm. While EDCs are similar to ADCs in basic com-
position, their novelty lies in the ability to act exclusively on extra-
cellular cell surface proteins, requiring neither internalization 
nor breakdown of the conjugate. Several of the experiments con-
ducted in this study yielded data in support of this assertion. First, 
during the construction of the initial EDCs, data demonstrated 
that linker length factored significantly and specifically to EDC 
activity. Second, antibodies to proteins either known to interact 
or hypothesized to interact with the NKA yielded potent EDCs. 
Third, the active EDCs never exhibited activity above background 
when tested on cell lines not expressing their antibody’s target. 
This was true even after all cell lines were determined to be sen-
sitive to unconjugated free drug CG1. Studies to further inves-
tigate the putative plasma membrane associated protein-protein 
interactions are ongoing. The results also indicate that EDCs do 
not require internalization or breakdown. First, all active EDCs 
target two extracellular regions of membrane bound proteins and 
therefore should not necessitate internalization. Second, since 
antibodies specific to poorly-internalizing targets such as CD20 
can render potent EDCs,31,39 internalization of the antibody is not 
required. Third, the data presented showed a strong correlation 
between EDC linker length and EDC activity (EDCs with lon-
ger linkers were more active). If EDCs required breakdown, one 
would presume that linker length would not greatly affect activ-
ity, especially given the data showing that linker-CG1 constructs 
(void the antibody) displayed more activity when the linkers were 
shorter. Forth, the data presented shows that neither EDC-DYS 
nor EDC-CD38 are actively internalized. Taken together, these 
findings support the notion that EDCs require neither internaliza-
tion nor breakdown. This is an important finding because it could 
add additional targets to the current arsenal of safe and effective 
antibody drug conjugates as today’s ADCs require internaliza-
tion. Not requiring internalizing may also be beneficial in the 
fight against cancer as many drug resistant pathways involve the 
upregulation of ATP-binding cassette (ABC) transporters, which 
include plasma membrane pumps that extrude toxins and drugs 
out of the cell. A noninternalizing EDC should therefore not be 
affected by such pathways.
The results also indicate that even when freshly prepared nor-
mal cell types expressing both EDC targets were tested, they were 
much less sensitive to EDC affects than cancer cells. This was never 
the case for unconjugated free drug CG1. One simple explanation 
for this would be that the EDC specific proteins simply do not 
interact or the interaction occurs less frequently on normal cells, 
a situation that could be due to surface protein expression levels, 
protein trafficking differences, lipid raft micro-domains or other 
cell surface character variations. Whatever the reason, it may pro-
vide a unique opportunity to selectively target cells existing in a 
diseased state and further increase the TI, which has hindered the 
clinical progress of CGs for indications beyond heart disease. This 
now needs to be confirmed in cancer patients.
Figure 6 EDC-CD20 has dose dependent antitumor activity that surpasses Rituximab in DLBCL tumor models. Data are plotted as group mean 
tumor volumes post tumor implant, with standard error of the mean (SEM) which are indicated by vertical bars. (a) CB17SCID mice (n = 6 per group) 
bearing s.c. SU-DHL-4 xenograft tumors of an average size of 250 mm3 were treated with vehicle (dashed line) EDC-CD20 (circle) or Rituximab 
(diamond) at 5 mg/kg using the dosing schedule of q6dx2 via i.p. injection. (b) CB17SCID mice (n = 6 per group) bearing s.c. SU-DHL-4 xenograft 
tumors of an average size of 250 mm3 were treated with either vehicle (dashed line) or EDC-CD20 dosed at 0.5 mg/kg (triangle), 1.5 mg/kg (square), 
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The in vivo efficacy results provide support that EDCs act in 
a dose- and antibody-dependent fashion. Furthermore, responses 
achieved by EDC technology required 350-fold fewer CG1 equiv-
alents to achieve results similar to unconjugated free drug CG1. 
The findings suggest that protein-protein interactions between the 
NKA and the other EDC-targeted proteins are maintained and 
readily accessible in in vivo models. The data also indicates that 
Rituximab’s ability to bind CD20 can be used to target a potent 
inhibitor of the NKA with EDC technology. Finally, the data pre-
sented show that like cardiac glycosides, EDCs act by inhibiting 
the NKA, thus far an untapped mechanism of action for cancer 
patient therapy. This suggests that EDCs may be useful in treating 
cancers, especially multi-drug-resistant cancers. Efforts geared 
toward this possibility are ongoing.
Each of the five cell surface proteins targeted by the potent 
EDCs discussed have cancer-related functions. Expression of dys-
adherin, the NKA gamma 5 subunit, has previously been shown to 
be a prognostic indicator for late-stage metastatic cancers.40 CD20 
is best known as being a target for Rituximab and other clinically 
approved antibody therapies. The CD38 target is gaining atten-
tion from recent approval of Daratumumab (Darzalex; Janssen 
Biotech, Horsham, PA), the first clinically approved antibody spe-
cific to human CD38 for the treatment of multiple myeloma. The 
CD56 target is a marker for natural killer cells, certain forms of 
cancer, is associated with cell migration and invasion, and is the 
target for the ADC known as IMGN901.41,42 Finally, CD147 has 
been linked to a number of important cancers and has been found 
to induce the expression of matrix metalloproteinases as well as 
the lactate transporters MCT1 and MCT4.43 Clearly more targets 
will be identified as this work progresses but the list so far shows 
great promise at targeting CGs and other molecules that act on 
extracellular membrane targets.
In conclusion, for the first time, the results of this study highlight 
a new and effective paradigm for antibody-directed targeting of small 
molecules. The new molecules highlighted are termed extracellular 
drug conjugates or EDCs because they do not require internaliza-
tion or breakdown. The results also bring a new level of precision 
to cancer targeting showing that EDCs depends on the proximity 
effects of two targets and not simply the expression of those targets. 
The research presented here also provides a framework upon which 
future research initiatives can be delineated and structured with the 
end goal being the development of precision therapies capable of 
selectively targeting and safely treating diseased tissues.
MATERIALS AND METHODS
Reagents and antibodies. Reagents and solvents were used sans further 
purification unless otherwise specified Polyethylene glycol-derivatives 
(Quanta Biodesign, Plain City, OH), Proscillaridin-A (Molekula, Gillingham, 
UK), N-phthalimido-tetracetyl-glucosamine (Carbosynth, Berkshire, UK), 
p-nitrophenyl phosphate (Pierce Biotechnology, Waltham, MA), and tri(2-
carboxyethyl)phosphine hydrochloride (Hampton Research, Aliso Viejo, 
CA). Antibodies used: Mouse IgG1 α-dysadherin clone NCC-M53 (National 
Cancer Center, Tokyo, Japan), mouse IgG1 α-EMMPRIN clone 8D12 (eBio-
sciences, San Diego, CA), mouse IgG1 α-NCAM clone HCD56 (Biolegend, 
San Diego, CA), mouse IgG1 α-CD29 clone MEM-101A (Biolegend), mouse 
IgG1 α-CD47 clone CC2C6 (Biolegend), mouse/human chimeric IgG1 α-
CD20 Rituximab (Genentech, South San Francisco, CA), IgG1 α-CD38 clone 
SUN4B7 (F. Malavasi, Torino, Italy). Human IgG Protein-A purified from nor-
mal serum (Innovative Research, Novi, MI) was used make EDC-Control. 
Antibodies used for western blotting were; ab175213, ab181602, ab76020, 
ab2873, and ab137055 (Abcam, Cambridge, MA).
Synthesis of CG1 antibody conjugates. Antibody conjugates were pre-
pared by reduction-alkylation of antibody inter-chain disulfides. Briefly, 
between 1–10 mg/ml of antibody in dulbecco’s phosphate-buffered saline 
(DPBS) was reduced in the presence of 1 mmol/l diethylenetriaminepen-
taacetic acid (DTPA) and 8 molar equivalents of tris(2-carboxyethyl) phos-
phine (TCEP) at 37 °C for 2 hours. These mixtures were then cooled in an 
ice bath, at which time 9.6 molar equivalents of a maleimide activated CG 
PEG compound (CG1 PEG2, CG1 PEG12, CG1 PEG24, or CG1 PEG36) 
was added and allowed to react for 30 minutes on ice. Residual maleimide 
groups were then quenched by the addition of a 1.5 equivalent excess 
of L-cysteine (based upon maleimide), which was allowed to react for 
30 minutes at room temperature (RT). Resulting antibody conjugates were 
separated from Cys-capped reagents by forced dialysis using Amicon Ultra 
30,000 molecular weight cut-off (MWCO) centrifugal filters (Millipore) 
and DPBS buffer exchange (3×). Conjugates were stored (4 °C) in DPBS at 
concentrations ranging from 1–10 mg/ml.
DAR calculation. Drug antibody ratios were determined by measuring 
absorbance of conjugates, antibodies (Ab) and free drug (drug) at both 280 
and 299 nm. Next, the following constants were determined; [Constant Ab] 
= A299Ab/A280Ab; [Constant Drug] = A299drug/A280drug. Next, absor-
bance of antibody drug conjugate was measured [A280 and A299]. Drug 
loading = drug concentration/antibody concentration. Using the following, 
drug loading was determined. A280Ab = A280 – (A299 – [Constant Ab] × 
A280)/([Constant drug] – [Constant Ab]). A299drug = A299 – [Constant 
Ab] × A280Ab. Antibody concentrations = A280Ab/204,000 M-1cm-1 
(varies depending on antibody). Drug concentration = A299drug/5623 
M-1cm-1. A299drug = drug component. A280Ab = antibody component.
Cell lines. A375, A549, BF01, FaDu, H520, H69, HT29, MRC-9, PANC-1, 
Ramos, RPMI-8226, SU-DHL-4, SU-DHL-8, U937 (ATCC), and LOX-
IMVI (NCI) cells were grown in ATCC/NCI recommended media supple-
mented with 50 µg/ml gentamycin (GIBCO). HUAEC and HREpC cell 
lines were maintained in Endothelial Cell Growth Medium 2 and Renal 
Epithelial Cell Growth Medium 2 (PromoCell GmbH). All cells were 
grown at 37 °C in a humidified atmosphere with 5% CO2.
PBMC testing. PBMC from healthy donors were immediately plated 
(2 × 105/ml) in Roswell Park Memorial Institute (RPMI) 1640 medium 
plus 10% fetal calf serum (FCS) and treated with EDC for 20 hours. Cells 
were then collected and stained with fluorescein isothiocyanate (FITC)-
conjugated annexin-V (BioLegend) and propidium iodide (Invitrogen) 
for 15 minutes at room temperature. Apoptosis was measured using a 
FACSCanto flow cytometer (Becton-Dickinson) and evaluated with the 
FlowJo software.
Fluorescent antibody staining. Cells were stained with 1 µg/ml of pri-
mary antibodies and 5 µg/ml goat anti-mouse IgG, DyLight 488 (Pierce 
Biotechnology) in DPBS with 1.5% fetal bovine serum (FBS) for 30 min-
utes, washed twice, and imaged using a Nikon Diaphot-TMD inverted fluo-
rescence microscope. PBMC from healthy donors were plated (2 × 105/ml) 
in RPMI 1640 10% FCS and treated with EDC for 20 hours, collected, 
and stained with FITC-conjugated Annexin-V (BioLegend) and propid-
ium iodide (Invitrogen) for 15 minutes at room temperature. Apoptosis 
was measured using a FACSCanto flow cytometer (Becton-Dickinson) 
and evaluated with the FlowJo software. Early apopstosis was defined as 
Annexin V-positive, PI-negative and late apoptosis as Annexin V-positive, 
PI-positive.
Cell proliferation/cytotoxicity assays. For Cell Titer-Glo assays, cells 
were treated 24 hours after plating and Cell Titer-Glo Luminescent Cell 
Viability Assay (Promega) was performed 72 hours later. Luminescence 
measurements were performed using a Wallac Victor2 Model 1420-041 
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assay plate reader (Perkin Elmer, Gaithersburg, MD). EC50 values for each 
test agent were determined with GraphPad Prism 5 software (GraphPad).
Cell morphology analysis. A549 cells (~ 1,500) were plated in 96-well 
plates in full media containing 125 nmol/l Sytox Green, treated as indi-
cated with EDCs/steroidal glycosides after 24 hours, and imaged by phase-
contrast with an Incucyte Zoom (Essen Biosciences) using a 20× objective. 
Images were adjusted using Incucyte Zoom software (Essen Biosciences).
siRNA combination studies. A549 cells (~370) were reverse transfected 
in 384-well plates with 0.2, 0.12, or 0.04 picomoles of total Dharmacon 
Smartpool siRNAs and 0.06 μl of RNAiMax transfection reagent per well in 
full media containing 125 nmol/l Sytox Green if needed for analsysis. After 
24 hours, EDCs/steroidal glycosides were added and cells were imaged 
over a period of 5 days using the Incucyte Zoom (Essen Biosciences) or 
after 72 hours Cell Titer-Glo Luminescent Cell Viability Assay was per-
formed. Percent confluence at 5 days was determined using Incucyte 
Zoom Software (Essen Biosciences). At the end of 5 days, Triton X100 (1% 
final concentration) was added to each well and plates were rescanned to 
determine the total number of cells per well. Percent dead was calculated 
by dividing the number of Sytox Green-positive cells before Triton X100 
addition the total number per well. Percent confluence and percent dead 
data were analyzed and EC50 curves were plotted using GraphPad Prism 
5 software (GraphPad).
EDC internalization studies. Experiments were performed following 
Polson et al.35 Briefly, H460 cells (large cell lung cancer) were seeded into 
96-well, clear bottom, tissue culture treated plates at a density of 10,000 
cells/well in 100 µl media (RPMI 1640 with 10% fetal bovine serum and 50 
µg/ml Gentamicin)/well. Cells were incubated at 37 °C and 7% CO2 for 24 
hours. NCC-M53 and EDC-DYS were diluted in media, with and without 
protease inhibitors (10 µg/ml leupeptin, and 5 µmol/l pepstatin), to a final 
concentration of 2 µg/ml added to wells (100 µl/well) at time points −21 or 
−3 hours. At time 0 hours, media was removed by aspiration and the wells 
were washed 1× with DPBS + 1.5% FBS. Cells were then fixed with 4% 
formaldehyde in phosphate buffered saline (PBS) for 20 minutes at room 
temperature and permeabilized with 0.1% Triton X-100 in PBS for 15 min-
utes at room temperature. For controls, cells that did not receive antibody 
during culture were stained with M53 or M53-PEG24-CEN09-106 after 
fixation and permeabilization. Cells were then washed twice with DPBS + 
1.5% FBS. Goat anti-mouse IgG Dylight 488 conjugate (Thermo) second-
ary was diluted to 5 µg/ml in DPBS + 1.5% FBS and added to all wells at 
100 µl/well and incubated for 30 minutes at room temperature. Cells were 
again washed, and then viewed with Nikon Diaphot TMD inverted trin-
ocular fluorescence phase contrast microscope with Ph2 20X DL objec-
tive. Pictures were captured using an Olympus E-450 Digital SLR camera, 
and the brightness of fluorescence images were adjusted using GIMP 2.6 
(GNU Image Manipulation Program, The GIMP Development Team 
(International)).
Xenograft studies
General. EDCs were diluted in sterile saline for injection and dosed 
as indicated. Paclitaxel (LC laboratories) was dissolved as a 15 mg/ml in 
ethanol/Cremophor EL (1:1) stock solution, and stored at −80 °C. This 
stock solution was diluted 1.5 mg/ml in saline just before injection at 10 µl 
per gram of mouse body weight. Gemcitabine (LC laboratories) in saline 
stored at room temperature and dosed at 120 mg/kg. CHOP consists of 
a single intraperitoneal injection of 30 mg/kg cyclophosphamide (Sigma-
Aldrich), 2.475 mg/kg doxorubicin (LC Laboratories), and 0.375 mg/kg 
vincristine (LC Laboratories), in addition to oral dosing of 0.15 mg/kg 
prednisone (Sigma-Aldrich) once a day for 5 days. Tumor sizes were cal-
culated using the formula: Tumor volume (mm3) = (w2 × l)/2 where w = 
width and l = length in mm of a given tumor.
Non–small-cell-lung cancer xenograft. A549 tumor line was maintained 
by serial subcutaneous transplantation in athymic nude mice. A549 tumor 
fragments (~ 1 to 2 mm3 each) were implanted subcutaneously via trocar 
into the left flank of female HRLN nu/nu mice of 8–12 weeks old (Harlan 
Laboratories). Animals were randomized (six mice per group; four 
groups) and treatment initiated when tumors reached an average volume 
of 100 mm3. Tumor-bearing mice were dosed as shown in Figure 4. Every 
4 to 7 days tumor volume was assessed for each group using calibrated 
vernier calipers and results were plotted against time from day of first dose.
Pancreatic cancer xenograft. PANC-1 tumor cells were maintained by 
serial subcutaneous transplantation in athymic nude mice, and PANC-1 
tumor fragments (1 mm3) were implanted subcutaneously into the right 
flank of female HRLN nu/nu mice of 8–12 weeks old (Harlan Laboratories). 
Mice bearing tumors of 90–130 mm3 were randomized by tumor size and 
segregated into nine groups (n = 10 mice/group). Group mean tumor vol-
umes ranged from 106–112 mm3 and individual tumor volumes from 63–
172 mm3. Tumor-bearing mice were dosed as shown in Figure 3. Twice per 
week tumor volume was assessed for each group using calibrated vernier 
calipers and results were plotted against time from day of first dose.
B-cell lymphoma xenograft. Ramos and SU-DHL-4 cells were washed, 
suspended in Dulbecco’s PBS (Hyclone), and inoculated subcutaneously 
(1 × 107 cells suspended in 0.2 ml per mouse) into the flanks of female 
SHO mice 28 to 35 days old (Ramos) and CB17SCID mice 36–42 days 
old (SU-DHL-4) (Charles River Laboratories). When mean tumor size 
reached ~250 mm3, mice were divided into groups (five mice/group- 
Ramos; six mice/group- SU-DHL-4) with the same mean tumor size and 
dosed by intraperitoneal injection.
General analytical chemistry. 1H-NMR and 13C-NMR analyses were 
performed using a Varian Mercury Plus 300 MHz NMR spectrometer 
(Department of Chemistry, UW-Madison). ESI-MS spectra were obtained 
using an AB Sciex QTRAP, and ESI-HRMS spectra were generated with 
an Agilent LC/MSD TOF instrument. All samples (in methanol or 1:1 
acetonitrile-water) were injected into the electrospray source at a rate of 
30 µl/minute. MALDI-MS spectra were obtained with an ABI Sciex 4800 
TOF/TOF mass spectrometer using α-cyano-4-hydroxycinnamic acid as 
an ionization matrix (Biotechnology Center of the UW-Madison). high 
performance liquid chromatography (HPLC) analyses were performed on 
a Waters modular system consisting of a Delta 600 fluid handler, a 600 
controller, a 2777 auto sampler, and a 2996 PDA detector. For analytical 
HPLC, a Gemini C18 5 µm, 110 Å, 250 × 4.6 mm column was used with a 
100 µl injection loop. Semi-preparative HPLC was performed on the same 
system via manual injection with a 500 µl injection loop and Gemini C18 5 
µm, 110, 250 × 10.0 mm column. TLC analysis was performed using EMD 
glass-backed TLC plates precoated with a 0.25 mm layer of silica gel 60 F254 
(EMD Chemicals, Gibbstown, NJ). TLC protocols were developed based 
on one or more of the following detection techniques: (i) UV at 254 nm, (ii) 
iodine vapors, and (iii) a solution of 2.5 g phosphomolybdic acid, 1.0 g ceric 
sulfate, 6.0 ml sulfuric acid, and 94 ml water, followed by heating. Flash 
chromatography was performed with a Biotage SP4 flash chromatography 
instrument (Charlottesville, VA) using Biotage cartridges. Absorbance val-
ues for the antibodies and CG1 were determined on a Beckman DU530 
UV/VIS spectrophotometer.
Synthesis of CG1 and PEG derivatives: 1-O-allyl-α-D-arabinopyranoside 
8. D-Arabinose 7 (100 g, 666 mmol) and Na2SO4 (100 g, 703 mmol) were 
suspended in allyl alcohol (1 l, 14.65 mol) at RT. To this suspension was 
added concentrated H2SO4 (10.4 ml, 187 mmol). The mixture was stirred 
overnight at 85 °C. The solids were removed by filtration and washed 
with allyl alcohol (2 × 300 ml). The combined filtrate was concentrated in 
vacuo. The crude material was purified by flash chromatography (silica gel, 
CH2Cl2 to CH2Cl2-MeOH 80:20) to give 8 as an off-white solid (75 g, 60%).
1-O-allyl-2,3-di-O-benzoyl-α-D-arabinopyranoside 9. To a solution of 
8 (75 g, 394 mmol) in pyridine (800 ml) at 0 °C was added benzoyl chloride 
(101 ml, 867 mmol) over 2 hours. The reaction mixture was stirred at RT 
for 16 hours. The solvent was removed in vacuo. The crude material was 
purified by flash chromatography (silica gel, hexanes-EtOAc 8:2 to 6:4) to 
give 9 as a thick oil (45 g, 29 %).
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1-O-allyl-2,3-di-O-benzoyl-4-O-trif luromethanesulfonyl-α-D-
arabinopyranoside 10. To a solution of 9 (20.0 g, 50 mmol) in dry CH2Cl2 
(100 ml) and pyridine (16.2 ml, 200 mmol) at 0 °C was added triflic anhy-
dride (10.6 ml, 62.7 mmol). The reaction mixture was stirred at 0 °C for 15 
minutes. CH2Cl2 (500 ml) was added to the solution and the organic layer 
was washed with cold 1N HCl (200 ml), saturated NaHCO3 (200 ml) and 
brine (200 ml). Organics were then dried (Na2SO4), and concentrated in 
vacuo to give crude 10 as a yellow oil. The crude material was carried on 
without further purification.
1-O-allyl-2,3-di-O-benzoyl-4-deoxy-4-azido-α-L-xylopyranoside 11. 
Crude 10 (26.6 g, 50.1 mmol) was dissolved in N,N-dimethylacetamide 
(100 ml) and sodium azide (6.37 g, 98 mmol) was added to the solution. 
The mixture was stirred overnight at RT. The solvent was removed in vacuo, 
and the residue was dissolved in CH2Cl2 (750 ml). The organic layer was 
washed with water (2 × 200 ml) and brine (200 ml), dried (Na2SO4) and 
concentrated in vacuo. The crude material was purified by flash chroma-
tography (silica gel, hexanes:EtOAc 8:2 to 6:4) to give 11 as a thick colorless 
oil (17.5 g, 84 %).
2,3-Di-O-benzoyl-4-deoxy-4-azido-L-xylopyranoside 12. To a solution 
of 11 (15.7 g, 37.1 mmol) in CH2Cl2-MeOH (100 ml, 90:10) under argon 
was added PdCl2 (0.66 g, 3.7 mmol). The reaction mixture was stirred 
overnight at RT, filtered through a pad of celite and concentrated. The 
crude material was purified by flash chromatography (silica gel, hexanes-
EtOAc 8:2 to 5:5) to give 12 as a thick colorless oil and as 2:1 mixture of 
α/β (11.1 g, 78 %).
2,3-di-O-benzoyl-4-deoxy-4-azido-α-L-xylopyranoside 1-trichloroaceti-
midate 13. To a solution of 12 (11.1 g, 28.9 mmol) in dry CH2Cl2 (180 ml) 
under argon was added trichloroacetonitrile (29 ml, 289.5 mmol) at 0 °C, 
followed by DBU (0.8 ml, 5.2 mmol). The reaction mixture was stirred at 0 
°C for 1 hour. The solvent was removed in vacuo. The crude material was 
purified by flash chromatography (silica gel, hexanes-EtOAc 9:1 to 8:2) to 
give 13 as a yellow oil (14.04 g, 92%).
Scillarenin 14. To a solution of proscillaridin A (3 g, 5.6 mmol) in etha-
nol (60 ml) at 40 °C was added sodium acetate buffer (170 ml, 0.02 M, pH 
4.0), followed by naringinase (1.03 g, Sigma-Aldrich, Cat# N1385). The 
reaction mixture was stirred overnight, diluted with ethanol (200 ml), fil-
tered through a pad of Celite and the filtrate was concentrated in vacuo. 
The residue was purified by flash chromatography (silica gel, CH2Cl2-
MeOH 98:2 to 90:10) to give 14 as an off-white solid (1.9 g, 90%).
Scillarenin-2’,3’-di-O-benzoyl-4’-deoxy-4’-azido-β-L-xylopyranoside 
15. A solution of 13 (14.04 g, 26.6 mmol) in dry CH2Cl2 (100 ml) was 
added to a suspension of activated 4 Å molecular sieves (2 g) in dry CH2Cl2 
(100 ml) under argon at 0 °C. Scillarenin (14, 10.2 g, 26.6 mmol) was 
then added to the mixture. After 10 minutes of stirring at 0 °C, Zn(OTf)2 
(0.96 g, 2.66 mmol) was added. The reaction mixture was stirred at 0 °C 
for 2 hours. The reaction was quenched with Et3N (3.7 ml, 26.6 mmol). 
The mixture was filtered and the solvent was removed in vacuo. The crude 
material was purified by flash chromatography (silica gel, hexanes-EtOAc 
7:3 to 1:1) to give 15 as a white powder (15.93 g, 80%).
Scillarenin-4’-deoxy-4’-azido-β-L-xylopyranoside 16. A solution of 15 
(15.66 g, 20.9 mmol) in MeOH-CH2Cl2 (590 ml, 75:25) was cooled to 0 °C. 
NaOMe (25% in MeOH, 2.1 ml, 10.3 mmol) was subsequently added and 
the reaction mixture stirred at RT for 1.5 hours. The reaction was quenched 
with acetic acid (0.6 ml, 10.3 mmol) and the crude material was purified by 
flash chromatography (silica gel, CH2Cl2-MeOH 98:2 to 90:10) to give 16 
as a white powder (2.6 g, 23%).
Scillarenin-4’-deoxy-4’-amino-β-L-xylopyranoside (CG1). To a solution 
of 16 (2.6 g, 4.8 mmol) in THF-H2O (50 ml, 92:8) was added PPh3 (2.5 g, 
9.6 mmol). The reaction mixture was stirred at 45 °C for 2.75 hours. The 
mixture was then added dropwise to Et2O at 0 °C. The resulting precipitate 
was filtered and washed with Et2O and dried in air to give 1 as a slightly 
yellow powder (2.0 g, 81)
Compound CG1 PEG12. To a solution of 1 (36 mg, 0.069 mmol) and 
maleimide-PEG12-NHS ester (50 mg, 0.058 mmol) in N,N-dimethyl-
acetamide (1 ml) was added Et3N (0.08 ml, 0.577 mmol). The reaction 
mixture was stirred at RT for 1 hour and solvent subsequently removed in 
vacuo. The crude material was purified by flash chromatography (silica gel, 
CH2Cl2-MeOH 95:5 to 80:20) to give 3a as a slightly yellow oil (30 mg, 41%).
Compound CG1 PEG24. To a solution of 1 (250 mg, 0.485 mmol) 
and maleimide-PEG24-NHS ester (676 mg, 0.485 mmol) in N,N-
dimethylacetamide (1 mL) was added Et3N (0.26 mL, 1.45 mmol). The 
reaction mixture was stirred at RT for 1 hour. The solvent was removed in 
vacuo. The crude material was purified by HPLC.
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